Suzhou Transcenta Therapeutics Co.Ltd.
Albumin-bound paclitaxel(Suzhou Transcenta Therapeutics Co., Ltd.)은 Solid Cancer 표적 ADC로, Advanced Cancer; Gastric Cancer 영역에서 개발·상용화 중입니다. 작용기전: Targeting the vitamin D receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 36% (ClinicalTrials.gov NCT00462423). 차별점: novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose.
Solid Cancer
Advanced Cancer; Gastric Cancer
Recruiting
Govitecan in Untreated, Advanced Triple-Negative
lipid nanoparticles, nanostructured lipid carriers, polymeric, micelles, dendrimers), inorganic (c
novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose
Targeting the vitamin D receptor
apoptosis via upregulated Bax and Caspase-3 levels
biomarker analysis
resistance to oxaliplatin, fluorouracil, and albumin-bound paclitaxel
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Suzhou Transcenta Therapeutics Co.Ltd.
Albumin-bound paclitaxel(Suzhou Transcenta Therapeutics Co., Ltd.)은 Solid Cancer 표적 ADC로, Advanced Cancer; Gastric Cancer 영역에서 개발·상용화 중입니다. 작용기전: Targeting the vitamin D receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 36% (ClinicalTrials.gov NCT00462423). 차별점: novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose.
Solid Cancer
Advanced Cancer; Gastric Cancer
Recruiting
Govitecan in Untreated, Advanced Triple-Negative
lipid nanoparticles, nanostructured lipid carriers, polymeric, micelles, dendrimers), inorganic (c
novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose
Targeting the vitamin D receptor
apoptosis via upregulated Bax and Caspase-3 levels
biomarker analysis
resistance to oxaliplatin, fluorouracil, and albumin-bound paclitaxel
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.